Trial no.:
|
PACTR202108873035929 |
Date of Approval:
|
16/08/2021 |
Trial Status:
|
Registered in accordance with WHO and ICMJE standards |
|
TRIAL DESCRIPTION |
Public title
|
Additive value of platelet rich plasma (PRP) in surgical treatment of stable vitiligo .A randomized double blind comparative study. |
Official scientific title |
The value of adding platelet rich plasma (PRP) to non cultured epidermal cell suspension (NCES) in surgical treatment of stable vitiligo .A randomized double blind comparative study. |
Brief summary describing the background
and objectives of the trial
|
Vitiligo is a quite distressing and challenging skin disorder. Vitiligo surgery; with non cultured epidermal cell suspension (NCES) being one of the most commonly used techniques, provides hope for otherwise resistant cases. However, in spite of improving the overall success rate of vitiligo treatment, it fails to achieve successful repigmentation in a good number of cases.
Platelet rich plasma (PRP)has high growth promoting ,healing and regenerative capacity being rich in a multitude of growth factors like platelet derived growth factor (PDGF), transforming growth factor beta (TGF b), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and insulin‐like growth factor (IGF).
We assume that these growth factors, especially bFGF in PRP, would stimulate melanocyte migration along with the stimulation of keratinocytes and fibroblast proliferation. The addition of PRP to NCES thus should increase the rate and extent of repigmentation.
Our objective is to assess the value of adding of PRP to the NCES via detecting percent reduction in the extent of vitiligo lesions treated by PRP suspended NCES compared to ones treated by saline suspended NCES through point counting technique as well as comparing improvement in pigmentation using VESTA Score (vitiligo extent score for a target area).
|
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Skin and Connective Tissue Diseases |
Sub-Disease(s) or condition(s) being studied |
|
Purpose of the trial |
Treatment: Surgery |
Anticipated trial start date |
01/08/2021 |
Actual trial start date |
|
Anticipated date of last follow up |
30/11/2021 |
Actual Last follow-up date |
|
Anticipated target sample size (number of participants) |
30 |
Actual target sample size (number of participants) |
|
Recruitment status |
Completed |
Publication URL |
|
|